Rallybio Corp (RLYB)
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Rallybio Corporation
Nasdaq bars a compliance period at 1:250
- 1:8Reverse splitFeb 6, 20268 shares → 1
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $858K | $636K | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | 34.9% | - | - | - | - | - | - |
| Cost of Revenue | $92K | $39.51M | $150K | $0 | $109K | $62K | $26K |
| Gross Profit | $766K | -$38.87M | -$150K | $0 | -$109K | -$62K | -$26K |
| Gross Margin | 89.3% | -6111.8% | - | - | - | - | - |
| Research and Development | $19.6M | $41.51M | $53.54M | $40.69M | $26.91M | $17.63M | $11.37M |
| Selling, General, and Administrative | $14.32M | $18.32M | $25.39M | $27.2M | $18.74M | $7.67M | $6.28M |
| Other | -$5.09M | -$38.21M | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $28.83M | $21.63M | $78.93M | $67.88M | $45.65M | $25.3M | $17.64M |
| Operating Income (EBIT) | -$28.06M | -$60.5M | -$78.93M | -$67.88M | -$45.65M | -$25.3M | -$17.64M |
| Operating Margin | -3270.9% | -9511.9% | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $10K | $49K | $39K |
| Interest Income | $2.19M | $4.22M | $6.15M | $1.96M | $54K | $171K | $197K |
| Other Income (Expense) | $19.09M | $2.72M | $4.37M | $1.23M | -$1.36M | -$1.16M | $79K |
| Income Before Tax (EBT) | -$8.98M | -$57.77M | -$74.56M | -$66.65M | -$47.01M | -$26.46M | -$17.46M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | -$15K | $0 |
| Net Income | -$8.98M | -$57.77M | -$74.56M | -$66.65M | -$47.01M | -$26.45M | -$17.63M |
| Net Income Margin | -1046.4% | -9084.1% | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -1.59 | -10.64 | -14.72 | -16.72 | -11.68 | -9.52 | -4.40 |
| Diluted EPS | -1.59 | -10.64 | -14.72 | -16.72 | -11.68 | -9.52 | -6.32 |
| Weighted Average OS | 5.63M | 5.44M | 5.06M | 3.98M | 4.02M | 2.78M | 2.78M |
| EBITDA | -$27.97M | -$60.37M | -$78.78M | -$67.72M | -$45.39M | -$25.24M | -$17.39M |
| EBITDA Margin | -3260.1% | -9491.4% | - | - | - | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $31.37M | $13.9M | $24.49M | $56.96M | $175.33M | $140.23M | $19.46M |
| Short-Term Investments | $23.36M | $51.61M | $85.44M | $112.04M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $54.74M | $65.51M | $109.93M | $168.99M | $175.33M | $140.23M | $19.46M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $2.52M | $995K | $2.05M | $1.05M | $395K | $0 | $0 |
| Total Current Assets | $61.25M | $67.84M | $114.79M | $179.5M | $180.87M | $141.26M | $20.92M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $198K | $267K | $592K | $909K | $511K | $287K | $199K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $239K | $30K | $805K | $310K | $488K |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $810K | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Assets | $1.01M | $267K | $831K | $939K | $1.32M | $597K | $687K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $62.26M | $68.11M | $115.62M | $180.44M | $182.19M | $141.86M | $21.61M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $126K | $278K | $976K | $1.11M | $603K | $1.58M | $857K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $212K | $848K | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $1.46M | $3.1M | $3.17M | $4.7M | $2.99M | $0 | $1.59M |
| Total Current Liabilities | $4.22M | $6.24M | $9.26M | $10.74M | $6.55M | $5.84M | $3.81M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $212K | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $32K | $12K | $941K |
| Total Long-Term Liabilities | $82K | $212K | $173K | $374K | $32K | $12K | $941K |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.3M | $6.45M | $9.44M | $11.12M | $6.58M | $5.86M | $4.75M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $37.14M |
| Common Stock | $4K | $4K | $4K | $4K | $3K | $2K | $230K |
| Retained Earnings | -$302M | -$293.02M | -$235.25M | -$160.68M | -$94.03M | -$47.01M | -$20.57M |
| Comprehensive Income & Other | $18K | $68K | $15K | -$214K | $0 | $0 | $56K |
| Other Stockholders' Equity | $359.95M | $354.67M | $341.43M | $329.99M | $269.63M | $183.01M | $37.2M |
| Total Equity | $57.96M | $61.65M | $106.18M | $169.32M | $175.6M | $136M | $16.86M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $62.26M | $68.11M | $115.62M | $180.44M | $182.19M | $141.86M | $21.61M |
| Supplementary Data | |||||||
| Total Debt | $176K | $154K | $392K | $555K | $0 | $0 | $0 |
| Net Debt | -$31.2M | -$13.75M | -$24.1M | -$56.4M | -$175.33M | -$140.23M | -$19.46M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$8.98M | -$57.77M | -$74.56M | -$66.65M | -$47.01M | -$26.45M | -$17.56M |
| Depreciation & Amortization | $92K | $131K | $150K | $167K | $109K | $62K | $26K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $103K |
| Stock-Based Compensation | $5.31M | $7.99M | $10.92M | $9.5M | $3.65M | $704K | $194K |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$152K | -$698K | -$99K | $487K | -$976K | $723K | $728K |
| Other Working Capital | -$4.04M | $440K | $4.38M | -$1.42M | -$2.8M | $1.4M | $1.34M |
| Total Working Capital Change | -$4.19M | -$258K | $4.28M | -$936K | -$3.78M | $2.12M | $2.07M |
| Other Non-Cash Items | -$22.05M | $627K | -$1.05M | $640K | $1.5M | $1.52M | $144K |
| Net Cash from Operating | -$29.81M | -$49.28M | -$60.27M | -$57.28M | -$45.53M | -$22.04M | -$15.03M |
| Investing Activities | |||||||
| Capital Expenditures | $0 | $0 | -$12K | -$54K | -$333K | -$137K | -$188K |
| Acquisitions | $0 | -$2M | -$2.25M | -$300K | -$2M | -$1.94M | $0 |
| Purchases of Investments | -$17.7M | -$48.93M | -$110.66M | -$201.32M | -$2M | -$1.94M | $0 |
| Sales of Investments | $46.47M | $84.42M | $138.33M | $89.5M | $2M | $1.94M | $0 |
| Other Investing Activities | $18.5M | $0 | $2.25M | $0 | -$2K | -$2K | $0 |
| Net Cash from Investing | $47.27M | $33.49M | $27.66M | -$112.17M | -$2.33M | -$2.07M | -$188K |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | - | - | - |
| Common Stock Issuance | $16K | $5.41M | $143K | $51.53M | $86.2M | $145.21M | $31.6M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | -$206K | $0 | -$455K | -$3.23M | -$319K | -$33K |
| Net Cash from Financing | $16K | $5.2M | $143K | $51.08M | $82.97M | $144.89M | $31.57M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $17.47M | -$10.59M | -$32.46M | -$118.38M | $35.1M | $120.78M | $16.35M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$29.81M | -$49.28M | -$60.27M | -$57.28M | -$45.53M | -$22.04M | -$15.03M |
| Capital Expenditure | $0 | $0 | -$12K | -$54K | -$333K | -$137K | -$188K |
| Free Cash Flow | -$29.81M | -$49.28M | -$60.28M | -$57.34M | -$45.87M | -$22.18M | -$15.21M |
| Cash at Beginning | $13.9M | $24.49M | $56.96M | $175.33M | $140.23M | $19.46M | $3.1M |
| Cash at End | $31.37M | $13.9M | $24.49M | $56.96M | $175.33M | $140.23M | $19.46M |